Analyst Reco. Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
13.28 ^USD	-4.73%		-5.14%	-38.72%

04-25	Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained	MT
04-25	Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained	04-25	MT
TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating	04-18	MT
Scotiabank Cuts Price Target on Sage Therapeutics to $19 From $34, Maintains Sector Outperform Rating	04-18	MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $17 From $25, Maintains Perform Rating	04-18	MT
BofA Securities Downgrades Sage Therapeutics to Underperform From Neutral, Adjusts Price Target to $14 From $24	04-17	MT
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating	03-26	MT
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating	02-15	MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating	02-15	MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk	02-15	MT
Wedbush Adjusts Sage Therapeutics' Price Target to $24 From $22, Keeps Neutral Rating	01-29	MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $23 From $20, Maintains Perform Rating	01-11	MT
Stifel Cuts Price Target on Sage Therapeutics to $20 From $22, Maintains Hold Rating	12-18	MT
Deutsche Bank Initiates Coverage on Sage Therapeutics With Hold Rating, $21 Price Target	12-12	MT
RBC Trims Price Target on Sage Therapeutics to $21 From $22, Keeps Sector Perform, Speculative Risk	11-08	MT
Wedbush Lifts Sage Therapeutics' PT to $22 From $21, Says Zurzuvae Pricing In-Line With Expectations; Maintains Neutral Rating	11-08	MT
Goldman Sachs Adjusts Price Target on Sage Therapeutics to $25 From $22, Maintains Neutral Rating	23-10-13	MT
RBC Trims Price Target on Sage Therapeutics to $22 From $25, Reflecting Company's Recent Cost Cuts, Keeps Sector Perform Rating	23-09-07	MT
Morgan Stanley Adjusts Price Target on Sage Therapeutics to $20 From $49, Maintains Equal-Weight Rating	23-08-09	MT
Truist Adjusts Sage Therapeutics' Price Target to $20 From $40, Keeps Hold Rating	23-08-08	MT
Goldman Sachs Downgrades Sage Therapeutics to Neutral From Buy, Price Target is $22	23-08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Analyst Reco.

Filters